KRP 105Alternative Names: KRP105
Latest Information Update: 20 Sep 2010
At a glance
- Originator Kyorin Pharmaceutical
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 07 Nov 2006 Preclinical trials in Hyperlipidaemia in Japan (unspecified route)